 |
인쇄하기
취소
|
ViroMed’s VM202 emerging as blockbuster medicine
ViroMed said on November 28 that the phase I study results of VM202, a gene-based medicine for cardiovascular disease (CVD) were presented in the Seoul National University Hospital’s clinical center.
The clinical results consolidated three clinical trials conducted in the US, China and Korea.
For the future clinical trial, ViroMed has submitted the IND application of a phase I clinical tr...
The clinical results consolidated three clinical trials conducted in the US, China and Korea.
For the future clinical trial, ViroMed has submitted the IND application of a phase I clinical tr...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.